Literature DB >> 15289373

Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion.

Katashi Okoshi1, Masaharu Nakayama, Xinhua Yan, Marina P Okoshi, Adam J T Schuldt, Mark A Marchionni, Beverly H Lorell.   

Abstract

BACKGROUND: Neuregulins are required for maintenance of acetylcholine receptor-inducing activity of nicotinic receptors in neurons and skeletal muscle, but effects of neuregulins on muscarinic receptors are not known. In the normal heart, parasympathetic activation counterbalances beta-adrenergic activation. To test the hypothesis that neuregulins modify parasympathetic function in the heart, we studied cardiomyocytes from mice heterozygous for neuregulin-1 gene deletion (NRG-1+/-) and examined the effects of beta-adrenergic stimulation on contractility in the presence and absence of the muscarinic agonist carbachol. METHODS AND
RESULTS: We evaluated contraction and intracellular Ca2+ transients ([Ca2+]i) in left ventricular (LV) myocytes loaded with Fluo-3 from NRG-1+/- and wild-type (WT) mice. Under baseline conditions (0.5 Hz, 1.5 mmol/L [Ca2+]o, 25 degrees C), characteristics of myocyte contraction/relengthening and systolic/diastolic [Ca2+]i were not different between WT and NRG-1+/- mice. The steady-state increases in fractional shortening (FS) and peak-systolic [Ca2+]i in response to isoproterenol were similar in both groups. In WT myocytes stimulated with isoproterenol, carbachol decreased FS, peak-systolic [Ca2+]i, and cAMP levels. In NRG-1+/- myocytes, carbachol did not attenuate either FS or peak-systolic [Ca2+]i, associated with the failure to decrease cAMP levels. Investigation of muscarinic receptor signaling showed no difference of LV protein levels of muscarinic M2 receptors or G protein Galpha(i1,2), Galpha(i3), and Galpha(o) subunits.
CONCLUSIONS: Cardiomyocytes deficient in neuregulin signaling are unable to adequately counterbalance beta-adrenergic activation by inhibitory parasympathetic activity. This mechanism may contribute to the known increased risk of heart failure in injured human hearts when neuregulin signaling is suppressed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289373     DOI: 10.1161/01.CIR.0000138109.32748.80

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

Review 1.  The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation.

Authors:  Brian Wadugu; Bernhard Kühn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

Review 2.  Angiogenic therapy for cardiac repair based on protein delivery systems.

Authors:  F R Formiga; E Tamayo; T Simón-Yarza; B Pelacho; F Prósper; M J Blanco-Prieto
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 3.  Evidence for impaired vagus nerve activity in heart failure.

Authors:  Steve Bibevski; Mark E Dunlap
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

Review 4.  Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.

Authors:  Cecilia Vasti; Cecilia M Hertig
Journal:  World J Cardiol       Date:  2014-07-26

Review 5.  The role of Neuregulin-1beta/ErbB signaling in the heart.

Authors:  Laura Pentassuglia; Douglas B Sawyer
Journal:  Exp Cell Res       Date:  2008-09-03       Impact factor: 3.905

6.  A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy.

Authors:  Jeffrey E Cohen; Brendan P Purcell; John W MacArthur; Anbin Mu; Yasuhiro Shudo; Jay B Patel; Christopher M Brusalis; Alen Trubelja; Alexander S Fairman; Bryan B Edwards; Mollie S Davis; George Hung; William Hiesinger; Pavan Atluri; Kenneth B Margulies; Jason A Burdick; Y Joseph Woo
Journal:  Circ Heart Fail       Date:  2014-06-05       Impact factor: 8.790

7.  Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

Authors:  D Lenihan; T Suter; M Brammer; C Neate; G Ross; J Baselga
Journal:  Ann Oncol       Date:  2011-06-10       Impact factor: 32.976

Review 8.  Neuregulin signaling and heart failure.

Authors:  Zhenggang Jiang; Mingdong Zhou
Journal:  Curr Heart Fail Rep       Date:  2010-03

Review 9.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 10.  Neuregulin in cardiovascular development and disease.

Authors:  Oghenerukevwe Odiete; Michael F Hill; Douglas B Sawyer
Journal:  Circ Res       Date:  2012-10-26       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.